OPTUMRx®

June 22, 2021

– IMPORTANT INFORMATION – COVID-19 Testing Claims Submission New York Medicaid

In addition to the notice provided on July 7, 2020 titled **COVID-19 Testing Claims Submission** and in response to the current novel Coronavirus (COVID-19) emergency situation and the state of New York Executive Order #202.24 and #202.82, OptumRx will now accept claim submissions for pharmacies providing COVID-19 testing (diagnostic and serology) in accordance with a Clinical Laboratory Improvement Amendments (CLIA) waiver. OptumRx is committed to making COVID-19 testing adjudication immediately available to increase the potential for widespread testing across our network for our members.

The details provided below are to assist our network pharmacy providers in submitting claims for members with Medicaid coverage in the state of **New York**.

Table 1. Billing Instructions for Lab Specimen Collection or CLIA Waived COVID-19 Testing, influenza, OR RSV testing

NCPDP D.0. Claim Segment Field	Value
436-E1 (Product/Service ID Qualifier)	Enter a value of **09** (HCPCS), which qualifies the code.
407-D7 (Product/Service ID)	Enter one applicable procedure code from Table 2.
411-DB (Prescriber ID)	Enter the Pharmacist National Provider Identifier (NPI) number.

Table 2. Code List and Reimbursement for Lab Specimen Collection or CLIA waived COVID-19 Testing

Code	Description	Reimbursement
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	$23.46
U0002*	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCov (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC	$51.31
87635*	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique	$51.31
87426* (effective 01/15/2021)	Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV-2, SARS-CoV-2 [COVID-19]).	$45.28
87811* (effective 01/15/2021)	Infectious agent antigen detection by immunoassay with direct optical (i.e., visual) observation; severe acute respiratory coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]).	$41.38

Table 3- Code List and Reimbursement for CLIA waived COVID-19, influenza, and/or RSV testing. (Effective date 5/20/21)

Code	**Description**	**Reimbursement**
87634	Infectious agent detection by nucleic acid (DNA or RNA); severe respiratory syncytial virus, amplified probe technique	$21.43
87807	Infectious agent detection by antigen detection byimmunoassay with direct optical observation; severe respiratory syncytial virus	$13.10
87502	Infectious agent detection by nucleic acid (DNA or RNA); influenza virus, for multiple types or sub-types, includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, first 2 types or sub-types.	$53.45
87804	Infectious agent detection by antigen detection by immunoassay with direct optical observation; influenza a/b.	$14.50
87428*	Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV-2, SARS-CoV-2 [COVID-19]) and influenza virus types a and b.	$73.49
87636*	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) and influenza virus types a and b, multiplex amplified probe technique.	$142.63

***Multiplex Tests**: the multiplex codes may be billed for dates of service on or after January 1, 2021. Multiplex codes not outlined in this guidance are not covered. Information regarding tests that are FDA approved and subject to CLIA Certificate of Waiver requirements can be found at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm

* *Pharmacies performing and billing for COVID-19 testing should not bill for specimen collection. Reimbursement for the test includes specimen collection and generating the lab report. Furthermore, pharmacies who are already being provided payment, from another source, for either lab specimen collection or for COVID-19 testing should not bill Medicaid in addition.*

OptumRx appreciates all Network Pharmacy Providers' additional efforts related to testing. Should you need any clarification regarding this notice, please call the phone number on the back of the member's ID card.